COMPEL
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatinOngoingOpen NCT04765059 on ClinicalTrials.gov ↗
Population
Loading…
Intervention
Loading…
Comparator
Loading…
Loading…